RedHill Biopharma Files 6-K, Mentions Press Release

TL;DR

RHBP filed a 6-K, press release attached - check it out.

AI Summary

RedHill Biopharma Ltd. filed a Form 6-K on September 5, 2024, reporting information as of that date. The filing indicates the company is a foreign private issuer and will file annual reports on Form 20-F. It also references an attached press release titled "RedHill Biopharma Regain".

Why It Matters

This filing provides an update on RedHill Biopharma's reporting status and signals the release of new information through an attached press release, which could impact investor understanding of the company's current activities.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign private issuer and does not contain significant new financial or operational information beyond referencing an attached press release.

Key Players & Entities

• RedHill Biopharma Ltd. (company) — Registrant
• September 5, 2024 (date) — Filing date
• Form 6-K (document) — Filing type
• Form 20-F (document) — Annual report form

FAQ

Key Financial Figures

• $1.00 — rican Depositary Shares (the "ADSs") of $1.00 per share or more for at least 10 conse

Filing Documents

• zk2431992.htm (6-K) — 25KB
• image00001.jpg (GRAPHIC) — 32KB
• 0001178913-24-002973.txt ( ) — 70KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: September 5, 2024 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer Press Release RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement TEL AVIV, ISRAEL & RALEIGH, N.C., September 5, 2024 -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it received confirmation from the Listings Qualifications Department of The Nasdaq Stock Market LLC (the "Listings Qualifications Department") that the Company had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market ("Nasdaq"), and is now compliant with applicable listing standards for continued Nasdaq listing. To regain compliance with Nasdaq Listing Rule 5550(a)(2), the Company was required to maintain a minimum closing bid price for its American Depositary Shares (the "ADSs") of $1.00 per share or more for at least 10 consecutive business days, which was achieved on September 3, 2024. About RedHill Biopharma RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs Talicia , for the treatment of Helicobacter pylori (H. pylori) infection in adults 1 , and Aemcolo , for the treatment of travelers' diarrhea in adults 2 . RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640) , a first - in - class oral broad-acting, host-directed SPHK2 selective inhibitor with potential for pandemic preparedness, targeting multiple indications with a U.S. government collaboration for development for Acute Rad

Forward Looking Statements

Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include, among others, statements regarding the Company's ability to maintain compliance with Nasdaq's minimum bid price and other continued listing requirements. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: market and other conditions; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that acceptance onto the RNCP Product Development Pipeline will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for opaganib for any indication; the risk that observations from preclinical studies are not indicative or predictive of results in clinical trials; the risk that the FDA pre-study requirements will not be met and/or that the Phase 3 study of RHB-107 in COVID-19 outpatients will not be approved to commence or if approved, will not be completed or, should that be the case, that we will not be successful in obtaining alternative non-dilutive development funding for RHB-107; the risk that RHB-107's late-stage development for non-hospitalized COVID-19 will not

View Full Filing

View this 6-K filing on SEC EDGAR